4.5 Article

Cognitive Development in Adults With Attention-Deficit/Hyperactivity Disorder: A Controlled Study in Medication-Naive Adults Across the Adult Life Cycle

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 72, Issue 1, Pages 11-16

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.09m05420pur

Keywords

-

Funding

  1. Alza
  2. AstraZeneca
  3. Bristol-Myers Squibb
  4. Eli Lilly
  5. Janssen
  6. McNeil
  7. Merck
  8. Organon
  9. Otsuka
  10. Shire
  11. National Institute of Mental Health (NIMH)
  12. National Institute of Child Health and Human Development
  13. Abbott
  14. Celltech
  15. Cephalon
  16. Esai
  17. Forest
  18. GlaxoSmithKline
  19. Gliatech
  20. Janssen, McNeil
  21. NARSAD
  22. National Institute on Drug Abuse
  23. New River
  24. Novartis
  25. Noven
  26. Neurosearch
  27. Pfizer
  28. Pharmacia
  29. The Prechter Foundation
  30. The Stanley Foundation
  31. UCB Pharma
  32. Wyeth
  33. Boehringer-Ingelheim
  34. UCB (Schwarz) Pharma
  35. Sepracor
  36. MGH Academy
  37. American Academy of Child and Adolescent Psychiatry (AACAP)
  38. NIMH
  39. Harvard University
  40. Reed Medical Education
  41. AACAP
  42. MGH
  43. Oxford University Press
  44. Sanofi Aventis
  45. NIH [R01MH57934]

Ask authors/readers for more resources

Objective: This study evaluated the association between attention-deficit/hyperactivity disorder (ADHD) and psychometrically defined cognitive variables across the adult life span, using data from a large controlled study of adults with and without ADHD. Method: Comparisons were made between 2 groups of adults: participants with DSM-IV-diagnosed ADHD who had never received pharmacotherapy for their ADHD (n=116) and 146 control participants. Subjects received a battery assessing IQ, neuropsychological measures, and academic testing. We modeled cognitive measures as a function of age and group status using linear regression. The study was conducted at Massachusetts General Hospital, Boston, between 1998 and 2003. Results: ADHD and control subjects maintained similar, statistically significant differences in all psychometrically assessed measures of cognition within each decade that was represented (all P values < .01). Conclusion: The negative impact of ADHD on multiple, nonoverlapping, psychometrically assessed measures of cognition remained constant across the life cycle, suggesting that the association between ADHD and cognition neither improves nor deteriorates across the life cycle. Clin Psychiatry 2011;72(1):11-16 (C) Copyright 2010 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available